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Hypoxia has been associated with poor local tumour control and relapse in many cancer sites, including carcinoma of the prostate.
This translational study tests whether breathing carbogen gas improves the oxygenation of human prostate carcinoma xenografts in
mice and in human patients with prostate cancer. A total of 23 DU145 tumour-bearing mice, 17 PC3 tumour-bearing mice and
17 human patients with prostate cancer were investigated. Intrinsic susceptibility-weighted MRI was performed before and during a
period of carbogen gas breathing. Quantitative R2* pixel maps were produced for each tumour and at each time point and changes in
R2* induced by carbogen were determined. There was a mean reduction in R2* of 6.4% (P¼0.003) for DU145 xenografts and 5.8%
(P¼0.007) for PC3 xenografts. In all, 14 human subjects were evaluable; 64% had reductions in tumour R2* during carbogen
inhalation with a mean reduction of 21.6% (P¼0.0005). Decreases in prostate tumour R2* in both animal models and human
patients as a result of carbogen inhalation suggests the presence of significant hypoxia. The finding that carbogen gas breathing
improves prostate tumour oxygenation provides a rationale for testing the radiosensitising effects of combining carbogen gas
breathing with radiotherapy in prostate cancer patients.
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The relationship of radiosensitivity to varying oxygenation and the
detrimental effects of hypoxia in human tumours was first shown
over 50 years ago (Gray et al, 1953; Tomlinson and Gray, 1955).
Since then, it has been established that hypoxia is an important
factor in radiotherapy treatment failure and has been associated in
clinical studies with poor local tumour control and relapse in many
cancer sites (Nordsmark et al, 1996; Fyles et al, 1998; Brizel et al,
1999; Movsas et al, 2002; Hoskin et al, 2003).
Eppendorf microelectrode measurements have been used to
invasively characterise the range and heterogeneity of oxygen
partial pressures in the prostate and show that hypoxic regions
exist in human prostate carcinoma (Movsas et al, 1999; Parker
et al, 2004). The outcome of radical radiotherapy for prostate
cancer is influenced by the presence of hypoxia. A study that
prospectively analysed 57 patients with localised disease showed
that hypoxic tumours had a significantly worse biochemical
relapse-free survival at 2 years (31 vs 92%, Po0.0001; Movsas
et al, 2002). Oxygenation status is therefore an additional
prognostic factor beyond the classic prognostic factors
(age, clinical stage, Gleason score and prostate-specific antigen)
that predicts radiation treatment failure in prostate cancer. A
modelling study based on these clinical data predicts an oxygen
enhancement ratio for prostate cancer of 1.4 (95% confidence interval
of 1.2–1.8) that is consistent with the in vitro OER measurements of
human tumour cell lines under chronic hypoxia conditions (Wang
et al, 2006). These data taken together suggest that hypoxia is likely to
be a valid therapeutic target in prostate cancer.
The rationale for using a high oxygen-content gas to improve
tumour oxygenation is that the resulting increase in arterial pO2
will enhance the diffusion of soluble oxygen into tissues. Carbogen
is a normobaric high oxygen content gas mixture, which is usually
administered at one of the two concentrations (95% O2 with 5%
CO2 or 98% O2 with 2% CO2). Carbogen has been shown to
improve the oxygenation of both experimental and human
tumours (Falk et al, 1992; Robinson et al, 1997; Powell et al,
1999; Rijpkema et al, 2002). This gas mixture increases intravas-
cular oxygen availability resulting in greater oxygen uptake by
tumours. It also transiently increases tumour blood flow (possibly
due to a vasodilatory effect mediated by CO2), which increases
oxygen delivery to regions of perfusion-limited hypoxia (Sibtain
et al, 2002). Extracellular tumour pH has been shown to decline in
response to carbogen gas breathing, particularly for large and
hypoxic tumours (McSheehy et al, 1998). A study in a murine
tumour model showed that the level of radiosensitisation achieved
is dependent on both the CO2 content of the inspired gas and the
duration of gas breathing (Hill et al, 1998).
Hypoxia modification has been shown to improve radiotherapy
outcomes in several tumour sites, including the use of carbogen
gas breathing in combination with hypofractionated, conventional
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sand hyperfractionated radiotherapy schedules (Overgaard and
Horsman, 1996). Despite this, there has been a paucity of
investigation into its value in prostate cancer. In this study, blood
oxygen level-dependent (BOLD) MRI, also called intrinsic
susceptibility MRI, has been used to show the changes in blood
oxygenation in response to carbogen inhalation in two animal
models and in human subjects. This imaging technique capitalises
on the differing magnetic properties of oxygenated and deoxy-
genated blood. Deoxyhaemoglobin is paramagnetic and acts as an
intravascular contrast agent because it brings about an increase in
the transverse relaxation rates of blood and surrounding tissues.
Microscopic field gradients in the vicinity of red blood cells and
vessels are modulated by the changes in the deoxyhaemoglobin
concentration, which leads to signal attenuation in susceptibility-
weighted MR images (Alonzi and Hoskin, 2006). Thus, the purpose
of this study was to evaluate changes in prostate tumour
oxygenation using BOLD MRI in response to carbogen breathing.
MATERIALS AND METHODS
Animal experiments
All animal experiments were performed in full compliance with UK
government regulations and local guidelines on animal welfare and
were approved by the local ethical review committee.
Cell culture and implant
DU145 and PC3 cells were incubated under 19.6% O2,5 %C O 2 and
75.4% N2 at 371C. Both cell lines were originally isolated from
patients with metastatic hormone refractory prostate cancer
(Mickey et al, 1977; Stone et al, 1978; Kaighn et al, 1979). The
cells were maintained in Dulbecco’s Modified Eagle Media
(DMEM) supplemented with 10% foetal calf serum (FCS), 2mM
L-glutamine, 100Uml
 1 penicillin and 100mgml
 1 streptomycin.
Tumours were initiated by injecting (2 10
6 cells) subcutaneously
into the rear dorsum of 8–10-week-old SCID mice. Animals were
selected for investigation when their tumours reached 8–10mm
geometric mean diameter.
Imaging for tumour hypoxia
Mice were sedated for each MRI scan using 200mlo f1 : 1 0
hypnorm in water, injected into the peritoneal cavity. Sedated mice
were placed in a 6-cm diameter quadrature birdcage coil (Varian,
Palo Alto, CA, USA) in a 4.7 tesla Varian MR system. A hot air
blower with continuous temperature monitoring was used to
maintain body temperature.
Initial T1-weighted sagittal and transverse scans were obtained
for localisation. Multiple spoiled gradient echo (GRE) images were
acquired on a single central slice with increasing echo times
(TE¼4–48ms, in 4ms steps), with TR 117ms, flip angle (a)4 5 1,
slice thickness 1mm, and field of view 40 45mm. Scanning time
was divided into three gas-breathing periods with mice breathing
air, carbogen (95% O2 and 5% CO2) and then air again. The first
air breathing period lasted 4min, followed by 10min of carbogen
breathing and then 4min breathing air. Images were obtained
every minute, resulting in 18 images for each xenograft. All gases
were administered at 1lmin
 1 (gases obtained from BOC, UK). A
vacuum-based gas scavenger was used to minimise changes in
oxygen content within the magnet bore. GRE images with the same
imaging parameters that were used for the baseline scan were
acquired every minute throughout the experiment.
Animal MR image analysis
Multiecho sequence images were processed using Matlab version 5
(Mathworks, Nantick, MA, USA). A region of interest (ROI) was
drawn around the tumour using the initial T1-weighted image. R2*
pixel maps were then calculated for each time point of the imaging
series. For each pixel, a straight line was fitted to a plot of lnSt
against TE for each pixel using a least-squares approach, of which
the gradient is intrinsic relaxivity ( R2*; s
 1).
Statistical analysis
Repeatability was assessed by comparing two of the baseline BOLD
sequences taken 1min apart during the air-breathing period at the
beginning of the carbogen experiment (time points two and three)
for each xenograft. Bland and Altman (1996a,b,c) statistics for
measuring repeatability were used. This gave a range, based on the
repeatability of the entire group, of the change required in any
given xenograft to be considered statistically significant at the
95% confidence level and not simply be due to the natural test
variability. The effect of hyperoxia on R2* was evaluated using the
time series of repeated BOLD MRI scans during carbogen
breathing. The first four baseline R2* measurements, before the
carbogen gas exposure was initiated, were averaged to give a single
baseline value. The remaining R2* values (measurements 5–18)
were subtracted from the baseline measurement to give a DR2*
value, that is, the change in R2* from baseline. Group significance
testing was performed using the paired two-tailed student’s t-test.
Correlation between baseline R2* and DR2* was assessed using
Pearson’s correlation coefficient.
Human testing
A total of 17 patients with prostate cancer (age¼56–76 years,
Gleason grade¼6–8, PSA¼1.9–32.0ngml
 1) that were due to be
treated with a radical prostatectomy procedure were recruited.
None had received hormonal treatment. Investigations were
performed after approval by a local institutional review board
and full ethics committee approval. Written informed consent was
obtained from each subject. The histological diagnosis of prostate
cancer was made by core biopsy in all patients. Patients were
imaged in a Symphony 1.5T MRI scanner (Siemens Medical
Systems, Erlangen, Germany) using phased array pelvic coils.
Imaging for tumour hypoxia
The small field-of-view images of T2-weighted anatomical scans
perpendicular to the urethra were used to stage tumours and to
identify tumour slice locations. Images were inspected for the
presence of a peripheral zone abnormality consistent with cancer.
An oncological radiologist inspected the images, and the slice
location for BOLD imaging was chosen.
For each patient, five spoiled gradient-echo images were
acquired for three slices through the prostate with varying TE
(5–60ms), TR¼100ms, flip angle¼401, FOV¼200mm, 256
2
matrix, and 8mm thickness from which R2* maps were calculated.
Imaging was performed at three time points: (1) initial BOLD MRI
(breathing room air) to determine baseline R2* values, (2) second
BOLD MRI (breathing room air) performed immediately after the
first BOLD scan to establish the repeatability of the BOLD
technique, (3) third BOLD scan initiated after 10min of carbogen
breathing. Carbogen was administered through a tight-fitting
facemask and continued for the duration of the BOLD acquisition.
A 98% O2 and 2% CO2 mixture was used to maximise patient
compliance (Powell et al, 1999).
MRI data analysis
Tumour ROIs were outlined using the T2-weighted anatomical
scans. In general, an irregular mass of low signal intensity seen on
the T2-weighted images was considered to represent tumour.
When an obvious malignant peripheral zone tumour was
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scontiguous with homogeneous low signal intensity in the central
gland, the ROI of interest was expanded to encompass the entire
visible abnormality. A consultant radiologist with a specialist
interest in prostate cancer imaging independently verified these
regions (ARP).
Voxel-based calculations were performed using DiffusionView
r
version 2.1.3, a customised analysis software package developed in
IDL (Research Systems; Boulder, CO, USA) at the Institute of
Cancer Research, London, UK. R2* maps were created by pixel-
by-pixel fitting of a straight line to a plot of lnSt against TE for each
pixel using a least-squares approach, of which the gradient is  R2*
(s
 1). Pixels with either negative or zero values were excluded from
the analysis.
Statistical analysis
The same statistical analysis as the animal study was used for the
human experiments, the only differences being that two rather
than four baseline (air-breathing) time points were available from
which to calculate the baseline R2* measurement and only a single
carbogen-breathing image was obtained.
RESULTS
Animal experiments
A total of 23 DU145 tumour-bearing mice and 17 PC3 tumour-
bearing mice were investigated. Baseline R2* values for the two
xenograft models overlapped and both showed marked hetero-
geneity ranging from 15.4 to 135.0s
 1 (Figure 1). The test proved
to be extremely repeatable with a coefficient of variation (wCV) of
3.4% for DU145 tumours and 2.2% for PC3 tumours. For an
individual xenograft, a reduction in R2* of 9.3% for DU145
tumours and 6.3% for PC3 tumours could be considered
significant at the 95% confidence level (i.e. not simply a result of
test variability). Analysis on an individual tumour by tumour basis
for DU145 and PC3 tumours showed that four (17.4%) of the
DU145 tumour-bearing mice and five (29.4%) of the PC3 tumour-
bearing mice had reductions in R2* that could be considered
statistically significant at the 95% confidence level (Figure 1).
Analysis of the two groups as a whole showed a mean reduction in
R2* of 3.52s
 1 or 6.4% (P¼0.003) for the DU145 tumours and
3.04s
 1 or 5.8% (P¼0.007) for the PC3 tumours.
The carbogen time series graphs show the temporal effect of
carbogen breathing on the oxygenation of the prostate cancer
xenografts (Figure 2). R2* values fall rapidly after the commence-
ment of carbogen breathing as tumour oxygen levels increase. By
the end of the experiment, the R2* values have essentially returned
to baseline. Interestingly, in both DU145 and PC3 tumours, R2*
values seem to begin a return towards their baseline reading before
the carbogen exposure had been terminated. For DU145 tumours,
this occurs after approximately 9min and with PC3 tumours, the
effect is seen earlier, at about 4–5min. Following the cessation of
carbogen breathing, R2* values for the DU145 xenografts seemed
to ‘overshoot’, finishing at a higher level than at baseline. However,
this difference was not statistically significant.
There was no correlation between the baseline R2* value and the
change in R2* following carbogen exposure, for either tumour type.
Human testing
All 17 patients completed the two baseline BOLD scans. One
patient was unable to tolerate carbogen breathing, due to a feeling
of claustrophobia while in the MRI scanner wearing a facemask. In
two other patients, it was not possible to locate tumour on the
imaging slices. This left 14 patients available for analysis.
Baseline R2* values for the human tumours were lower than
those found in the xenografts because of the magnetic field
strength dependence of R2* relaxivities (Blockley et al, 2008), and
also showed less heterogeneity (R2*¼7.1–29.2s
 1). The suscept-
ibility-weighted BOLD technique proved to be highly repeatable in
human prostate cancer with a wCV of 4.7%. For an individual
patient’s prostate tumour, a change in R2* of 1.95s
 1 (or 12.9%)
could be considered significant at the 95% confidence level.
Analysis of tumour regions on an individual patient-by-patient
basis showed that 9 of the 14 patients (64%) had reductions in
tumour R2* during carbogen exposure that could be considered
statistically significant at the 95% confidence level (Figure 3).
Analysis of the group as a whole showed a mean reduction in R2*
of 3.52s
 1 or 21.6% (P¼0.0005) for the prostate tumour ROIs.
As for the xenografts, there was no correlation between the
baseline R2* value and the change in R2* following carbogen
exposure.
DISCUSSION
This study is the first to have quantified the BOLD effect with the
calculation of R2* values in both prostate cancer xenografts and
human tumours (these results are remarkably concordant). Using
repeatability statistics, we were also able to confidently identify, on
an individual basis, whether or not there is an oxygen-enhancing
effect of carbogen breathing for every tumour. Two-thirds of the
prostate cancer patients had a statistically significant reduction in
R2* following carbogen exposure. These results expand on a
previous demonstration of an oxygen-enhancing effect of carbogen
breathing in the benign human prostate gland (Taylor et al, 2001).
The two xenografts used in this study are known to be hypoxic,
with median pO2 values shown to be 3.0–6.4mmHg when
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Figure 1 Baseline values and the effect of carbogen gas breathing on the median R2* value of individual DU145 xenografts (left panel) and PC3 xenografts
(right panel). Each line represents an individual tumour. Lines with filled black circles represent tumours with a change in R2* that was statistically significant at
the 95% confidence level and not simply a result of natural test variability. There was a mean reduction in R2* of 3.52s
 1 or 6.4% (P¼0.003) for the DU145
tumours and 3.04s
 1 or 5.8% (P¼0.007) for the PC3 tumours.
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sinvestigated in a study using the Eppendorf histograph (Teicher
et al, 1994). The same report also described the heterogeneity of
oxygenation measurements between xenografts that is corrobo-
rated by the wide variation in baseline R2* measurements seen in
the current study. The reason why there is a greater variation in
baseline oxygenation in the xenografts compared with human
tumours is unclear. One explanation may be that the xenografts
exhibited substantial and variable degrees of necrosis with a mean
of 18.1% (range¼0–74.9%) of the total cross-sectional PC3
tumour area being necrotic and a mean of 9.4% (range¼0–
35.7%) for DU145 tumours. In contrast, necrosis is not a major
feature of human prostate cancer. Areas of necrosis would have a
low R2* value because of the lack of viable red blood cell delivery.
These regions are surrounded by an area of diffusion-limited
hypoxia with a disorganised vascular network that results in a
fluctuant, unpredictable blood supply, and these areas would be
expected to have higher R2* values.
One may expect that the most hypoxic tumours should show the
greatest benefit from carbogen exposure. This has not been shown
for either xenograft or for the human tumours in this study, with no
correlations seen between the baseline R2* value and the change in
R2* following carbogen exposure. This lack of concordance has been
reported in earlier studies of various tumour types, using both
microelectrode and imaging methods for hypoxia detection (Teicher
et al, 1994; Howe et al, 1999; Powell et al,1 9 9 9 ;T a y l o ret al,2 0 0 1 ) .I t
would appear that it is not necessarily the most hypoxic tumours that
exhibit the greatest response from carbogen breathing. However, as
defined by R2*, tumours that demonstrate a clear response are
hypoxic. Also, it seems that separate areas of equivalent hypoxia
within a single tumour may not respond equally to carbogen
stimulation. These findings reflect the complexity and heterogeneity
of the microregional vascular and endocrine environment within
tumours. As a result, it is only possible to use BOLD-MRI to measure
the response to carbogen breathing, but not to predict which
tumours are likely to respond to carbogen exposure.
The use of BOLD-MRI for assessment of tissue hypoxia is based
on the assumption that oxygenation of haemoglobin is related to
blood arterial pO2 (as described by the oxygen-haemoglobin
dissociation curve), which is in equilibrium with oxygenation of
surrounding tissues. Several studies have shown that R2* changes
in response to vasomodulation with carbogen are temporally
correlated with changes in tissue pO2 (Al-Hallaq et al, 1998;
Robinson et al, 1999; Taylor et al, 2001). Tumours appear to differ
in their ability to respond to carbogen inhalation with only
50–60% of human tumours showing changes in R2* (Taylor et al,
2001). The reasons for even hypoxic tumours having limited and
heterogeneous responses are complex, but undoubtedly include
the fact that tumours may have adapted to widely different
perfusion environments. It is to be noted that even when vessels
are present, red blood cell transport through these vessels may not
be effective (Robinson et al, 2003). Thus, hypoxic tumours with
high blood volume (due to high microvessel density coupled with
large vessels) will have raised baseline R2* values. On the other
hand, hypoxic tumours with low or zero blood volume, due to
necrosis, lower microvessel density or due to small vessels, will
have lower baseline R2* values because of the lack of delivery of
red blood cells to tissues. Attempts have been made to combine
blood volume information with R2* maps to improve the
sensitivity and specificity for hypoxia detection (Alonzi et al,
2008). Once robust protocols are available, more accurate
estimation of the oxygen-enhancing effect of carbogen breathing
in prostate cancer may be possible.
Limitations of the BOLD-MRI technique used here are: (1) it
does not measure tissue pO2 directly (either in blood or in tissues
because of a non-linear relationship of R2* and tissue pO2);
(2) images obtained have low signal to noise ratio; (3) the current
implementation is single slice, but multislice sequences are now
available. The primary advantages of BOLD-MRI are there is no
need to administer exogenous radioactive contrast material, and
images at high temporal and with high spatial resolution can be
obtained and repeated as needed; it is possible to decouple the
effects of flow and deoxyhaemoglobin, which are intrinsic to native
BOLD images, and so to show the changes in oxygenation
independent of changes in the blood flow.
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Figure 2 The temporal effect of carbogen breathing on the oxygenation of the 23 DU145 xenografts (left panel) and 17 PC3 xenografts (right panel). R2*
values fall rapidly after the commencement of carbogen breathing (arrow), as tumour oxygen levels increase. In both DU145 and PC3 tumours, R2* values
seem to begin a return towards their baseline reading before the carbogen exposure was terminated (dotted arrow).
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Figure 3 The effect of carbogen gas breathing on the median R2* value
of 14 individual human prostate cancers (age¼56–76 years, Gleason
grade¼6–8, PSA 1.9–32.0ngml
 1). Each line represents an individual
tumour; lines with filled black circles represent tumours with a change in
R2* that was statistically significant at the 95% confidence level, and not
simply a result of natural test variability. There was a mean reduction in R2*
of 3.52s
 1 or 21.6% (P¼0.0005).
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sThe series of experiments reported in this study show
that prostate cancer is amenable to hypoxia modification
using carbogen gas breathing. Prostate tumour R2* decreases
by an average of 5.8–6.4% in animal models and by 21.6% in
human patients as a result of carbogen exposure. These results
support the clinical testing of the radiosensitising effect of
combining carbogen gas breathing with radiotherapy in prostate
cancer.
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